Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05987709 · ClinicalTrials.gov registry record · NA
Study of Colorectal Cancer Screening Options
A NA study of Colon Cancer, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 2,004
- Enrollment target
- 1
- Study location
NCT05987709 is a NA study of Colon Cancer that has completed, run by Kaiser Permanente. The registered enrollment target is 2,004 participants, below the 4,436-participant average among 97 other Colon Cancer trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05987709, a NA study of Colon Cancer, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,004 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST GuardantSHIELD Blood Test
Study Locations (1)
Oregon
- Kaiser Permanente Northwest - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,004 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2023-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05987709
The ClinicalTrials.gov registry entry for NCT05987709 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,004 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,436-participant average among 97 other Colon Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which GuardantSHIELD Blood Test is the first listed.
NCT05987709 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05987709 about?
NCT05987709 is a clinical study titled "Study of Colorectal Cancer Screening Options". The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.
What is the current status of trial NCT05987709?
This trial is currently completed. It is a NA study. The enrollment target is 2,004 participants. The study started on 2022-03-17. Estimated completion is 2023-06-15.
What conditions does trial NCT05987709 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT05987709?
The interventions under investigation include: GuardantSHIELD Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05987709?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05987709 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Resilience and Equity in Aging, Cancer, and Health (REACH)
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
PrehabPal: A Digital Tool to Help Older Adults Prepare for Cancer Surgery
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.